恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究*

doi:10.3969/j.issn.1672-5069.2022.03.006

摘要/Abstract

摘要： 目的探讨应用恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎(CHB)患者的短期效果和血清细胞因子水平变化。方法 2019年1月～2020年2月我院收治的98例CHB患者,被随机分为对照组49例和观察组49例,两组均接受恩替卡韦治疗,在此基础上,给予观察组加用甘草酸二铵口服,两组均持续治疗观察12个月。采用放射免疫法检测血清透明质酸 (HA) 、层粘连蛋白(LN) 、IV型胶原( CIV) 、III型前胶原(PIIIP) 水平,采用ELISA法检测血清白介素 2(IL- 2)、白介素4(IL- 4)、白介素 10(IL- 10)和肿瘤坏死因子α(TNF-α)水平,使用流式细胞仪检测外周血 T 细胞亚群。结果在治疗12个月末,观察组血清ALT复常率为87.8%,显著高于对照组的71.4%(P＜0.05);观察组血清ALT和AST水平分别为(32.3±6.9)U/L和(38.3±4.7)U/L,显著低于对照组【分别为(47.5±7.6)U/L和(52.9±5.1)U/L,P＜0.05】;观察组血清HA和PⅢP水平分别为(90.6±9.5)ng/mL和(141.6±32.6)ng/mL,显著低于对照组【分别为(126.8±14.6)ng/mL和(168.2±29.9)ng/mL,P＜0.05】;观察组血清IL-4和TNF-α水平分别为(48.8±7.9)ng/L和(11.3±1.9)ng/L,显著低于对照组【分别为(62.6±8.8)ng/L和(18.5±1.7)ng/L,P＜0.05】,而血清IL-10水平为(19.2±2.5)ng/L,显著高于对照组【(12.7±3.4)ng/L,P＜0.05】;观察组外周血CD4⁺细胞百分比和CD4⁺/CD8⁺细胞比值分别为(43.5±5.5)%和(1.6±0.2),显著高于对照组【分别为(38.4±4.7)%和(1.4±0.4),P＜0.05】。结论应用恩替卡韦联合甘草酸二铵治疗CHB患者可有效改善患者肝功能,抑制肝纤维化进程,控制体内炎症反应,改善免疫功能紊乱。

关键词: 慢性乙型肝炎, 恩替卡韦, 甘草酸二铵, 治疗

Abstract: Objective The purpose of this study was to observe the application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with chronic hepatitis B (CHB). Methods A total of 98 patients with CHB were enrolled in our hospital between January 2019 and February 2020, and were randomly divided into control (n=49) and observation group (n=49), receiving entecavir or entecavir and magnesium isoglycyrrhizinate combination therapy for 48 weeks. Serum hyaluronan (HA), laminin (LN), type-IV collagen (CIV) and type-III procollagen (PIIIP) levels were detected by radioimmunoassay. Serum interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) and tumor necrosis factor α (TNF-α) levels were detected by ELISA. The peripheral blood T lymphocyte subsets were detected by flow cytometry. Results At the end of 48 week observation, serum ALT normalization rate in the observation group was 87.8%, significantly higher than 71.4%(P＜0.05) in the control; serum ALT and AST levels in the combination group were (32.3±6.9)U/L and (38.3±4.7)U/L, both significantly lower than [(47.5±7.6)U/L and (52.9±5.1)U/L, respectively, P＜0.05] in the control; serum HA and PⅢP levels were (90.6±9.5)ng/mL and (141.6±32.6)ng/mL, both significantly lower than [(126.8±14.6)ng/mL and (168.2±29.9)ng/mL, respectively, P＜0.05] in the control; serum IL-4 and TNF-α levels were (48.8±7.9)ng/L and (11.3±1.9)ng/L, significantly lower than [(62.6±8.8)ng/L and (18.5±1.7)ng/L, respectively, P＜0.05], while serum IL-10 level was (19.2±2.5)ng/L, significantly higher than [(12.7±3.4)ng/L, P＜0.05] in the control; the percentage of peripheral blood CD4⁺ cells and the ratio of CD4⁺/CD8⁺ cells were (43.5±5.5)% and (1.6±0.2), both significantly higher than [(38.4±4.7)% and(1.4±0.4), respectively, P＜0.05] in the control group. Conclusion The application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with CHB could effectively improve liver function test normal, inhibit the process of liver fibrosis, which might be related to the inhibition of inflammatory reaction and modulation of immune system.

Key words: Hepatitis B, Entecavir, Magnesium isoglycyrrhizinate, Therapy

黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.

Huang Junrong, Wu Changru, Wu Jianlin. Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(3): 327-330.

参考文献

[1] 赖思敏,赖小丽,黄汐,等.核苷(酸)类似物经治序贯聚乙二醇干扰素治疗慢性乙型肝炎的荟萃分析.中国感染与化疗杂志,2019,36(5):489-494.
[2] Hees SV, Cuypers B, Bourgeois S, et al. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol, 2021,362(4):104283.
[3] Wang J, Guo S, Zeng M, et al. Observation of the curative effect of device-guided rehabilitation on respiratory function in stable patients with chronic obstructive pulmonary disease. Medicine,2019,98(8):e14034.
[4] Yang L, Zhong HZ, Xiao QL, et al. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models. J Med Virol,2020,92(12):26025.
[5] Rong G, Chen Y, Yu Z, et al. Synergisticeffect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-Blind, placebo-controlled trial. J Infect Dis, 2020,21(3):266-270.
[6] Zhang C, Wang A, Wang H, et al. Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: Preparation and in vitro and in vivo evaluation. Int J Pharm, 2019,5(4):27-34.
[7] Boglione L, Benedetto ID, Lupia T, et al. Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. Arch Virol,2021:166(4):1125-1131.
[8] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):V-XVI.
[9] Chen MB,Wang H,Zheng QH, et al. Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis. Medicine, 2019, 98(34):e16943.
[10] Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021,21(3):1016-1018.
[11] Yang YZ, Liu ZH, Wang SC, et al. Magnesium isoglycyrrhizinate alleviates fructose-induced liver oxidative stress and inflammatory injury through suppressing NOXs. Eur J Pharmaco, 2020,883(16):173314.
[12] Jiang W, Xu S, Guo H, et al. Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. J Cell Mol Med, 2020,24(13):15230.
[13] Li TS, Chen L, Wang SC, et al. Magnesium isoglycyrrhizinate ameliorates fructose-induced podocyte apoptosis through downregulation of miR-193a to increase WT1. Biochem Pharmacol, 2019,166(15):139-152.
[14] Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021,17(2):18-19.
[15] Xie C, Li X, Zhu J, et al. Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264.7 cells. Bioorgan Med Chem, 2019, 27(3):516-524.
[16] 涂杰霞,王安娜,廖若汐.干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究.实用肝脏病杂志,2019,22(5):648-651.
[17] Mak L, Lee C, Cheung K, et al. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long‐term nucleoside analogue. Liver Intl,2019,39(7):1217-1225.
[18] Lee SW, Kim SU. Tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue. Aliment Pharm Ther, 2020, 52(5):889-890.
[19] Mei F,Yu J, Li M, et al. Magnesium isoglycyrrhizinate alleviates liver injury in obese rats with acute necrotizing pancreatitis. Pathol Res Pract, 2018,215(1):30-35.
[20] Yang YZ, Zhao XJ, Xu HJ, et al. Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling. Acta Pharmacol Sin,2018,40(7):879-894.

恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*

Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[3]	罗珂, 丁莉, 刘美. 慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 335-338.
[4]	王广丽, 徐欢, 董丹丹, 黄荷. 慢性乙型肝炎患者血清HBV恩替卡韦耐药基因突变模式调查^*[J]. 实用肝脏病杂志, 2022, 25(3): 339-342.
[5]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[6]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[7]	姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.
[8]	柴晓哲, 朱霞峰, 骆成林, 王少峰. 泛基因型与特异基因型DAAs方案精准治疗基因1b型慢性丙型肝炎患者疗效对比分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 355-358.
[9]	胡春霞, 杨娇楠, 张丰晓, 胡敬华. 格卡瑞韦/哌仑他韦治疗基因1b型慢性丙型肝炎患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 359-362.
[10]	陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 371-374.
[11]	杨海华, 周聪, 沈国强, 尤晓红, 孟玲. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志, 2022, 25(3): 375-378.
[12]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[13]	沈扬林, 谭可平, 游忠岚, 陈婵, 陆晖, 甘琼萍, 覃国琦, 陆鹏. 血浆置换序贯双重血浆分子吸附系统治疗慢加急性乙型肝炎肝衰竭患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 387-390.
[14]	孙亚男, 曾庆环, 刘远志, 张世斌, 李鹏, 武永乐, 丁惠国. 伴有中/重度食管静脉曲张的慢加急性肝衰竭患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 391-394.
[15]	詹惠珍, 杜雅钦, 王松姣. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 395-398.